Tag: Amylin analogue

While both medications target metabolic health, semaglutide is a GLP-1 receptor agonist, whereas cagrilintide is an amylin analogue. Understanding the core difference between semaglutide and cagrilintide is crucial, as this distinction affects their mechanisms of action and overall clinical effects, particularly when used in the combined drug CagriSema.

Based on recent clinical trial data from Novo Nordisk, the investigational drug cagrilintide is administered via once-weekly subcutaneous injections. Understanding the approach to what is the dosing schedule for cagrilintide is important, especially since protocols differ between monotherapy and combination therapy with semaglutide.